364 related articles for article (PubMed ID: 26608819)
21. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
Altawalbeh SM; Alshogran OY; Smith KJ
Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
24. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
[TBL] [Abstract][Full Text] [Related]
27. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation.
Lip GY; Lanitis T; Kongnakorn T; Phatak H; Chalkiadaki C; Liu X; Kuznik A; Lawrence J; Dorian P
Clin Ther; 2015 Nov; 37(11):2476-2488.e27. PubMed ID: 26477648
[TBL] [Abstract][Full Text] [Related]
29. A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation.
Micieli A; Wijeysundera HC; Qiu F; Atzema CL; Singh SM
Med Decis Making; 2016 Apr; 36(3):366-74. PubMed ID: 26139448
[TBL] [Abstract][Full Text] [Related]
30. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Rognoni C; Marchetti M; Quaglini S; Liberato NL
Clin Drug Investig; 2014 Jan; 34(1):9-17. PubMed ID: 24135964
[TBL] [Abstract][Full Text] [Related]
31. Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile.
Lanas F; Castro C; Vallejos C; Bustos L; de La Puente C; Velasquez M; Zaror C
J Clin Epidemiol; 2017 Jun; 86():75-83. PubMed ID: 27756577
[TBL] [Abstract][Full Text] [Related]
32. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
[TBL] [Abstract][Full Text] [Related]
34. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Brereton N; Hertz DS; Holmes DR
Europace; 2016 Jul; 18(7):979-86. PubMed ID: 26838691
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M
Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada.
Hafeez A; Cipriano LE; Kim RB; Zaric GS; Schwarz UI; Sarma S
Pharmacoeconomics; 2024 Jan; 42(1):69-90. PubMed ID: 37596504
[TBL] [Abstract][Full Text] [Related]
38. [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].
Escolar-Albaladejo G; Barón-Esquivias G; Zamorano JL; Betegón-Nicolás L; Canal-Fontcuberta C; de Salas-Cansado M; Rubio-Rodríguez D; Rubio-Terrés C
Aten Primaria; 2016; 48(6):394-405. PubMed ID: 26832316
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain.
Barón Esquivias G; Escolar Albaladejo G; Zamorano JL; Betegón Nicolás L; Canal Fontcuberta C; de Salas-Cansado M; Rubio-Rodríguez D; Rubio-Terrés C
Rev Esp Cardiol (Engl Ed); 2015 Aug; 68(8):680-90. PubMed ID: 25498373
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
